Ningbo Menovo Stock Hits Day High with 10.02% Surge

Ningbo Menovo Pharmaceutical Co., Ltd. has experienced a significant surge in its stock performance, gaining 10.02% on March 13, 2026. The stock reached an intraday high of CNY 25.37, showcasing its strong market activity. Over the past year, Ningbo Menovo has outperformed the broader market, generating a return of 56.90%, compared to the China Shanghai Composite's return of 22.49%. In terms of financial metrics, the company has demonstrated notable growth, with a year-to-date performance of 31.86%. Additionally, its one-month performance stands at 19.78%, indicating a consistent upward trend. Despite challenges in long-term growth, as evidenced by a net sales growth rate of 3.82% and an operating profit decline of 7.49% over the last five years, the company has managed to maintain a relatively attractive valuation with a price-to-book ratio of 1.93. Ningbo Menovo's debt-to-equity ratio is 0.37, reflecting a manageable level of debt. The company also reported a robust debtors turnover ratio of 4.99 times, highlighting effective management of receivables. Overall, Ningbo Menovo's recent performance underscores its position within the pharmaceuticals and biotechnology sector.